Elevated clotting factor levels and venous thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 395-400

  Bertina, Rogier M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Elevated clotting factor levels; Factor IX; Factor VIII; Factor XI; Fibrinogen; Prothrombin; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; PROTEIN C; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

BIOSYNTHESIS; BLOOD LEVEL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; ENZYME POLYMORPHISM; HUMAN; PHENOTYPE; PLASMA CLEARANCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION FACTORS; HUMANS; VENOUS THROMBOSIS;

EID: 14044254724     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083835     Document Type: Conference Paper

References (74)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.
2. Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost 1999;82:601-609.
3. Bertina RM. Genetic approach to thrombophilia. Thromb Haemost 2001;86:92-103.
4. Arnout J, Vermijlen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003;1:931-942.
5. de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-1276.
6. Tans G, van Hylckama Vlieg A, Christella M, Thomassen LGD, Curvers J, Bertina RM, Rosing J, Rosendaal FR. Activated protein C resistance determined with a thrombin generation based-test predicts for venous thrombosis in men and women. Br J Haematol 2003;122:465-470.
7. Den Heijer M, Koster T, Blom J, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
8. Chandler WL, Rodgers GM, Sprouse JT, Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 2002;126:1405-1414.
9. Tripodi A. Levels of coagulation factors and venous thrombosis. Haematologica 2003;88:705-711.
10. Van Hylckama Vlieg A, Callas PW, Cushman M, Bertina RM, Rosendaal FR. Inter-relation of coagulation factors and D-dimer levels in healthy individuals. J Thromb Haemost 2003;89:429-437.
11. Lavigne G, Mercier E, Quere I, Dauzat M, Gris JC. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost 2003;1:2134-2139.
12. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-155.
13. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
14. Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V Leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000;20:1382-1386.
15. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719-722.
16. Van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-3682.
17. De Visser MCH, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001;85:1011-1017.
18. Meijers JCM, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701.
19. Koster T, Rosendaal FR, Briët E, Vandenbroucke JP. John Hageman's factor and deep vein thrombosis: Leiden Thrombophilia Study. Br J Haematol 1994;87:422-424.
20. Van Hylckama Vlieg A, Komanasin N, Ariëns RAS, Poort SR, Grant PJ, Bertina RM, Rosendaal FR. Factor XIII Val34Leu, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002;119:169-175.
21. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis. Blood 2000;95:2855-2859.
22. Koster T, Rosendaal FR, Briët E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995;85:2756-2761.
23. Damn A, Hylckama Vlieg A, Bendz B, Rosendaal FR, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387-4392.
24. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Büller HR. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9.
25. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997;77:825-8.
26. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII:C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000;83:10-13.
27. Kamphuisen PW, Eikenboom JCJ, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999;81:680-683.
28. Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 2001;115:156-158.
29. Lensen R, Bertina RM, Vandenbroucke JP, Rosendaal FR. High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 2001;114:380-386.
30. De Mitrio V, Marino R, Scaraggi FA, Di Bari L, Giannoccaro F, Petronelli M, Ranieri P, Tannoia N, Schiraldi O. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk of venous thromboembolism in heterozygous carriers of the factor V Leiden mutation. Blood Coagul Fibrinolysis 1999;10:409-416.
31. Tsai AW, Cushman M, Rosamund WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002;113:636-642.
32. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thrombosis. N Engl J Med 2000;343:457-462.
33. Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G. High plasma levels of factor VIII and risk of recurrence of venous thrombosis. Br J Haematol 2004;124:504-510.
34. Christiansen S, Koster T, Vandenbroucke JP, Rosendaal FR. Risk factors for recurrent venous thrombosis; a prospective folluw-up of the Leiden thrombophilia study (LETS). J Thromb Haemost 2003;(Suppl):OC148.
35. Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemost 1995;74:1198-1199.
36. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998,79:456-465.
37. Brinkhous KM, Sandberg H, Garris JB, Mattson C, Palm M, Griggs T, Read MS. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985;82;8752-8756.
38. de Lange M, Snieder H, Ariëns RA, Spector TD, Grant PJ. The genetics of haemostasis. Lancet 2001;357:101-105.
39. Souto JC, Almasy L, Borrell M, Gari M, Martinez E, Mateo J, Stone WH, Blangero J, Fontcuberta J. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000;101:1546-51.
40. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum genet 1985;37:89-101.
41. Kamphuisen PW, Lensen R, Houwing-Duistermaat JJ, Eikenboom JCJ, Harvey M, Bertina RM, Rosendaal FR. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol 2000;109:519-522.
42. Mansvelt EPG, Laffan M, McVey JH, Tuddenham EGD. Analysis of the F8 gene in individuals with high plasma factor VIII:C levels and associated venous thrombosis. Thromb Haemost 1998;80:561-565.
43. Soria JM, Almasy L, Souto JC, Buil A, Martinez-Sanchez E, Mateo J, Borrell M, Stone WH, Lathrop M, Fontcuberta J, Blangero J. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003;101:163-167.
44. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Jr., Montgomery RR. The effect of blood group on the diagnosis of von Willebrand disease. Blood 1987;69;1691-1695.
45. Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayén L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscl Thromb Vasc Biol 2000;20:2024-2028.
46. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CLJJ, Sixma JJ, van den Berg HM. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000;83:65-69.
47. de Visser MCH, Sandkuijl LA, Lensen RPM, Vos HL, Rosendaal FR, Bertina RM. Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost 2003;1:1771-1776.
48. Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999;93:4277-4283.
49. Harvey PJ, Keightley AM, Lam YM, Cameron C, Lillicrap D. A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels. Br J Haematol 2000;109:349-353.
50. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafonov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999;274:37685-37692.
51. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparin sulphate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001;276:11970-11979.
52. Bovenschen N, Herz J, Grimbergen JM, Lenting PJ, Havekes LM, Mertens K, van Vlijmen BJM. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003;101:3933-3939.
53. Löwe GDO, Woodward M, Vessey MP, Rumley A, Gough P, Daly A. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationship to hormone replacement therapy. Thromb Haemost 2000;83:530-535.
54. Weltermann A, Eichinger S, Bialonczyck C, Minar E, Hirschl M, Quehenberger P, Schönauer V, Kyrle PA. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2002;1:28-32.
55. Sweeney JD, Hoernig LA. Age-dependent effect on the level of factor IX.. Am J Clin Pathol 1993;99:678-678.
56. Kurachi K, Kurachi S. Genetic mechanisms of age regulation of blood coagulation. Factor IX model. Arterioscler Thromb Vasc Biol 2000;20:902-906.
57. Libourel EJ, Bank I, Meinardi JR, Balje-Volkers CP, Hamulyak K, Middeldorp S, Koopman MMW, van Pampus ECM, Prins MH, Buller HR, van der Meer J. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin actvatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002;87:1068-1073.
58. Gerdes VEA, Kraaijenhagen RA, Vogels EWM, ten Cate H, Reitsma PH. Factor XI gene analysis in thrombophila and factor XI deficiency. J Thromb Haemost 2004;2:1015-1017.
59. Vicente V, González-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica 1999;84:356-362.
60. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, Stumpflen AM, Schneider B, Lechner K, Kyrle PA. The risk of recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999;81:14-17.
61. Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, Vos HL. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 2001;85:1066-1070.
62. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE. Increased efficiency of mRNA 3′end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001;28:389-392.
63. Carter AM, Sachchithananthan M, Stasinopoulos S, Maurer F, Medcalf RL. Prothrombin G20210A is a bifunctional gene polymorphism. Thromb Haemost 2002;87:846-853.
64. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′end formation. J Thromb Haemost 2004;2:119-127.
65. Van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003;1:2677-2678.
66. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombosis. Blood 2000;1:1517-1532.
67. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003;1:1566-1574.
68. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan Vague I. Identification of polymorphisms in the promoter and the 3′ UT region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001;97:2053-2058.
69. Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thrombosis. Blood 2004;103:3773-3776.
70. Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneider M, Boffa M, Koschinsky M, van Tilburg NH, Nesheim ME, Bertina RM, Gomez Garcia EB. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-actvatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001;98:1992-1993.
71. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003;23:1122-1127.
72. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli VM, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001;86:510-517.
73. Morange PE, Aillaud MF, Nicaud V, Henry M, Juhan-Vague I. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers. Thromb Haemost 2001;86:1583-1584.
74. Zidane M, de Visser MC, ten Wolde M, Vos HL, de Monye W, Bertina RM, Huisman MV. Frequency of the TAFI -438 G/A and factor XIII Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Throm Haemost 2003;90:439-445.